All filters
Slidesets
Does hepatic impairment affect the exposure of monoclonal antibodies? - Qin Sun
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy- Haaland
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Elvitegravir pharmacokinetics during Pregnancy and Postpartum- Angela Colbers
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of Integrase Inhibitors - Giovanni Di Perri, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical case presentation - Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon- Le
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women- Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vitro- Xinning Yang, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Update on DDI guidelines of the FDA - in vivo- Kellie Reynolds, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
How to End the Global HCV Epidemic - the role of injectables- David Thomas, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda- Kay Seden
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception- Kimberly Scarsi, PharmD, MS, FCCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration- Patel
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Rifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir- Holly Rawizza
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now?- Craig Hendrix
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years- Mustafa IBrahim
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018
Slidesets
Differential brain tissue penetration of antiretrovirals and fluconazole- Katelyn Pastick
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018